



Candidates for Treasurer

Kazutaka Ikeda, MD, Japan



I am privileged to be nominated for election as CINP Treasurer (2018-2022).

Personal Background

I graduated from the Faculty of Technology at The University of Tokyo (B.Eng.) in 1989 and obtained my M.Med degree from Osaka University in 1991 and Ph.D. degree from Niigata University in 1995. While in Prof. Mishina's laboratory at Niigata University, I cloned cDNA for the NMDA GluN2D receptor channel subunit and produced mice that lacked this subunit. I also produced mice that lacked the glutamate GluD2 receptor channel subunit and revealed a pivotal role for this subunit in motor control. Furthermore, I started studies on the opioid system and G protein-activated inwardly rectifying potassium (GIRK) channels. As a research fellow at RIKEN Brain Science Institute (1995-2000), I continued opioid and GIRK research and started studies on the dopamine system. I was appointed Senior Research Fellow (2000), Acting Chair (2002), and Chair (2003) in the Department of Molecular Psychiatry, Tokyo Institute Psychiatry, and Leader of the Addiction Substance Project (2011) and Chair of the Department of Psychiatry and Behavioral Sciences at the Tokyo Metropolitan Institute of Medical Science (2015). While at these institutions, I continued studies on addiction, schizophrenia, analgesia, and neurodevelopmental disorders at the molecular, genetic, animal-behavioral, and clinical levels. I have approximately 300 publications on these topics in prominent scientific journals, including *Cell*, *Nature Neuroscience*, *Molecular Psychiatry*, *Nature Communications*, *Journal of Neuroscience*, and *Trends in Pharmacological Sciences*. I was awarded the Distinguished International Scientist Collaboration Program Award from the U.S. National Institute on Drug Abuse in 2004, among several other awards. I am serving as an Academic Editor of *PLoS One*, a Field Editor of *Alcoholism: Clinical and Experimental Research*, and an Editorial Board Member of several other journals.

Activities in CINP and Related Organizations

I have been a Fellow of CINP since 2010 and have participated in CINP World Congresses in 2010, 2012, 2014, and 2016 and the CINP Special Congress on Addiction and Mental Health in 2013 where I served as a Plenary Lecturer and member of the Scientific Program Committee. I am currently serving as CINP Councillor (2016-2018) and a member of the CINP Constitution and By-Laws Committee (2016-2018). I also served as a member of the International Scientific Programme Committee (ISPC) for the CINP 2016 World Congress. The Japanese Society of Neuropsychopharmacology (JSNP) has over 1200 members and is under the umbrella of CINP. I am currently President of JSNP (2016-2018). I also served as



Chair of the JSNP 2016 Annual Meeting in Seoul in conjunction with the CINP 2016 World Congress in Seoul. I am President-elect (2017-2018) of the Asian College of Neuropsychopharmacology (AsCNP), which has over 3000 members and is also under the umbrella of CINP. I am a member of the American College of Neuropsychopharmacology (since 2014) and have participated as a representative of AsCNP at the ACNP/AsCNP/CINP/ECNP Leaders' Meetings during the ACNP Annual Meetings since 2012. I am also a member of the Science Council of Japan (2014-2020).

Position Statement

CINP has contributed to the innovative development of pharmacotherapy for the treatment of mental disorders and the growth of modern psychiatry for over 60 years. Especially in recent years, CINP has played a pivotal role in securing the future of drug discovery for central nervous system disorders. CINP proposed 10 action plans at the CINP 2013 Summit Meeting and is currently executing them. If elected, I would like to contribute to the financial fairness and stability of CINP and execution of its action plans. Academia and industry should collaborate with each other to overcome the world crisis of psychopharmacology while bearing in mind that the first action plan of CINP is "Code of Conduct." I would like to contribute to the presence of CINP in Asia where great numbers of people will start to use central nervous system drugs in the near future. My research projects involve researchers from a broad range of scientific disciplines, including genetic scientists, molecular biologists, biochemists, behavioural scientists, psychologists, and clinicians. I have fostered integrity in my clinical/basic research exchanges. I will continue to foster these attributes within CINP. I will work together with members of the CINP Executive Committee, Council, and College to maintain its leadership role in the field of neuropsychopharmacology worldwide. I will also collaborate with representatives of neuropsychopharmacology and brain science societies to achieve the goals of CINP by strengthening the links between them. It will be a great honor for me to further the mission of CINP by serving as CINP Treasurer.



Dan Rujescu, MD, Germany



I am Chair of the Department of Psychiatry, Psychotherapy and Psychosomatics of the University of Halle, Germany. I received my medical degree from the Universities Heidelberg and Essen. From 1993-1995 I worked as a physician at the Department of Psychiatry of the University of Mainz. Afterwards, I moved to the Department of Psychiatry of the University of Munich where I became Head of the Division of Molecular and Clinical Neurobiology. During his time in Munich I became a senior physician, a medical specialist in psychiatry and psychotherapy, a full Professor for Psychiatry, Head of the Alzheimer Memorial Center, as well as Deputy Head of the Department.

I can refer to an extensive list of publications comprising more than 350 original papers. Most of my research is funded through national and especially international third-party funding including eight EU funded projects, three genome-wide genotyping initiatives of the Wellcome Trust (WTCCC), one DFG priority program, one project of the Bavarian Research Foundation, two R01 projects of the National Institutes of Health and one BMBF project within the National Genome Research Network.

I am member of several national and international scientific societies. Within the World Society of Biological Psychiatry (WFSBP) I am head of the “Genetics” task force, furthermore, within the Colloquium Internationale Neuro-Psychopharmacologicum (CINP) I was councilor and chair of the “Ethics committee”. Additionally, I am head of the “Genetics of Suicide and Neurobiology” task force of the International Association for Suicidal Prevention (IASP) and fellow of the International Academy of Suicide Research (IASR).

Based on my previous research I have been awarded the following prizes: in 2006 the NARSAD Independent Investigator Award (William & Gloria Paul Family Foundation), in 2007 the Kraepelin Research Award, in 2008 the Dr. Paul Janssen Schizophrenia Research Award, in 2008 the Kraepelin-Alzheimer medal, and in 2010 the European BMS Prevention Award in Psychiatry.

I am mostly involved in the research of genetic factors and biomarkers of psychiatric diseases. The Department is involved in extensive academic and industrial national and international genome and post-genome efforts (e.g. genome wide association studies, next generation sequencing etc.). The major focus of my research is on a multidimensional translational approach to neuropsychiatric diseases and behavioral phenotypes at genetic, molecular, cellular, structural, functional, cognitive and behavioural levels. The group is recruiting and characterizing one of the largest groups of psychiatric patients and controls with intermediate phenotypes.



The International College of Neuropsychopharmacology (CINP) is a worldwide organisation where I am an active member since many years. CINP hold meetings all over the world with the aim to promote research and education on a worldwide basis. For me it is always a great opportunity to attend these meetings, to present own research and to have fruitful discussions with other researchers all over the world. One highlight within my career was to be Co-Chair of the Local Organising Committee of the 26th CINP Congress held in Munich in 2008 with 3500 attendees. Besides that, I had the honor to be Councillor of the CINP (2010-2012), Co-Chair of the Committee “Credentials & Membership” (2010-2012), Co-Chair of the “Website Committee” (2014-2016) and Chair of the “Ethics Committee” (2014-2016).

In future, I would wish to work actively on the organization of further meetings and e.g. to submit a proposal to the Executive Committee with the wish to hold a Thematic or Regional Meeting in my area.

One further point of my work is the membership in the Editorial Board of the International Journal of Neuropsychopharmacology. I truly enjoy to review newest manuscript on research and to be an active member of this field.

Nevertheless, I enjoyed working within the Think Tank of the CINP and to present all these new ideas within the International Journal of Neuropsychopharmacology.

The current development of CNS drug research. Wegener G, Rujescu D.

Int J Neuropsychopharmacol. 2013 Aug;16(7):1687-93.

It would be an absolute joy and honor to implement my extensive experience in the context of the office of Treasure within the CINP.